Eterna Therapeutics Stock Today
| ERNA Stock | USD 0.27 0.01 3.36% |
PerformanceModest
| Odds Of DistressHigh
|
Eterna Therapeutics is trading at 0.27059999 as of the 20th of March 2025, a 3.36 percent decrease since the beginning of the trading day. The stock's open price was 0.28. Eterna Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of October 1992 | Category Healthcare | Classification Health Care |
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Eterna Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 52.24 M outstanding shares of which 186.62 K shares are currently shorted by private and institutional investors with about 0.64 trading days to cover. More on Eterna Therapeutics
Moving together with Eterna Stock
Moving against Eterna Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Eterna Stock Highlights
| President CEO | Sanjeev Luther | ||||
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, IT, Computers, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | ||||
Eterna Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eterna Therapeutics' financial leverage. It provides some insight into what part of Eterna Therapeutics' total assets is financed by creditors.
| |||||
Eterna Therapeutics (ERNA) is traded on NASDAQ Exchange in USA. It is located in 1035 Cambridge Street, Cambridge, MA, United States, 02141 and employs 8 people. Eterna Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 14.47 M. Eterna Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 52.24 M outstanding shares of which 186.62 K shares are currently shorted by private and institutional investors with about 0.64 trading days to cover.
Eterna Therapeutics currently holds about 19.41 M in cash with (15.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Eterna Therapeutics Probability Of Bankruptcy
Ownership AllocationEterna Therapeutics holds a total of 52.24 Million outstanding shares. Eterna Therapeutics shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 62.33 percent of Eterna Therapeutics outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Eterna Ownership Details
Eterna Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 16.9 K | |
| Blackrock Inc | 2024-12-31 | 14.9 K | |
| Streettalk Advisors Llc | 2024-12-31 | 14.8 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 12.8 K | |
| One8zero8, Llc | 2024-12-31 | 10.9 K | |
| Bank Of America Corp | 2024-12-31 | 295 | |
| A. Montag & Associates Inc | 2024-12-31 | 212 | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 140 | |
| Jpmorgan Chase & Co | 2024-12-31 | 59.0 | |
| Ci Private Wealth Llc | 2024-12-31 | 262.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 257.3 K |
Eterna Therapeutics Historical Income Statement
Eterna Stock Against Markets
Eterna Therapeutics Corporate Management
| Andrew Jackson | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Susan McClatchey | VP Quality | Profile | |
| Sandra Gurrola | Principal Finance | Profile | |
| Megan Yung | Chief Officer | Profile | |
| Roger MD | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.26) | Revenue Per Share | Quarterly Revenue Growth 8.549 | Return On Assets | Return On Equity |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.